Get the Stockscreener App
257.58
1.20%
-3.12
After Hours:
257.58
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $257.58, with a volume of 933.43K.
It is down -1.20% in the last 24 hours and up +4.14% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$260.70
Open:
$260.14
24h Volume:
933.43K
Relative Volume:
0.90
Market Cap:
$37.60B
Revenue:
$5.26B
Net Income/Loss:
$1.44B
P/E Ratio:
26.36
EPS:
9.7713
Net Cash Flow:
$1.76B
1W Performance:
+2.02%
1M Performance:
+4.14%
6M Performance:
+1.31%
1Y Performance:
+8.62%
1-Day Range:
$256.99
$261.04
1-Week Range:
$250.32
$262.87
52-Week Range:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
257.58 | 38.05B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ISRG
Intuitive Surgical Inc
|
535.00 | 191.90B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
207.11 | 59.36B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
79.00 | 39.13B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
44.12 | 33.62B | 27.43B | 1.27B | 1.01B | 1.5829 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Should ResMed's (RMD) Earnings Beat and Margin Gains Require Action From Investors? - Yahoo Finance
ResMed Inc. (NYSE:RMD) Embodies Quality Investing Principles - Chartmill
A Look At ResMed (RMD) Valuation After Earnings Beat And Strong Start To Fiscal 2026 - Yahoo Finance
Is It Time To Reassess ResMed (RMD) After Recent Sleep Care Tailwinds? - Yahoo Finance
Resmed promotes new chief strategy officer from within - MassDevice
Reflecting On Patient Monitoring Stocks’ Q3 Earnings: ResMed (NYSE:RMD) - Barchart.com
Shorts Report: Can ResMed Inc maintain sales growthWeekly Investment Summary & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Nordea Investment Management AB Acquires 26,629 Shares of ResMed Inc. $RMD - MarketBeat
Sumitomo Mitsui Trust Group Inc. Buys 4,222 Shares of ResMed Inc. $RMD - MarketBeat
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term - sharewise.com
ResMed (RMD): Buy, Sell, or Hold Post Q3 Earnings? - TradingView — Track All Markets
ResMed Inc. Announces Change in Board Leadership - MSN
ResMed Chairman Emeritus Peter Farrell Sells 2,000 Shares Under Trading Plan - TipRanks
ResMed CEO Michael Farrell Exercises Options and Sells Shares Under 10b5-1 Plan - TipRanks
ResMed updates CDI and share structure for December 2025 - MSN
Bogart Wealth LLC Boosts Position in ResMed Inc. $RMD - MarketBeat
Aug PostEarnings: What dividend growth rate does ResMed Inc offerJuly 2025 Gainers & Real-Time Buy Signal Notifications - baoquankhu1.vn
What you need to know ahead of ResMed's earnings release - MSN
Zacks Research Comments on ResMed's Q2 Earnings (NYSE:RMD) - MarketBeat
The Truth About ResMed Inc.: Is This Sleep Tech Stock Quietly Going Viral? - AD HOC NEWS
Oregon Public Employees Retirement Fund Has $4.58 Million Stock Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. Reports Changes in Beneficial Ownership - MSN
How ResMed Inc. stock performs in easing cyclesIndex Update & Reliable Intraday Trade Alerts - ulpravda.ru
Resmed Insider Sold Shares Worth $497,660, According to a Recent SEC Filing - marketscreener.com
Insider Selling: ResMed (NYSE:RMD) Director Sells 2,000 Shares of Stock - MarketBeat
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus
Resmed director Farrell sells $497k in shares By Investing.com - Investing.com UK
Resmed director Farrell sells $497k in shares - Investing.com
SG Americas Securities LLC Acquires 47,758 Shares of ResMed Inc. $RMD - MarketBeat
Robeco Institutional Asset Management B.V. Sells 11,596 Shares of ResMed Inc. $RMD - MarketBeat
ResMed officer Brett Sandercock discloses planned sale of 1,000 shares under trading plan - MSN
How ResMed Inc. (Common Stock) (RMEA) stock correlates with oil marketsWeekly Trend Summary & Weekly Return Optimization Plans - ulpravda.ru
Will ResMed Inc. stock gain from lower inflationJuly 2025 Catalysts & Expert Curated Trade Setups - ulpravda.ru
Why ResMed Inc. (RME) stock is listed among top recommendations2025 Short Interest & Accurate Trade Setup Notifications - ulpravda.ru
EV Market: How ResMed Inc. (Common Stock) (RMEA) stock correlates with oil marketsPortfolio Return Report & Pattern Based Trade Signal System - ulpravda.ru
Michael Farrell Sells 4,991 Shares of ResMed (NYSE:RMD) Stock - MarketBeat
Resmed Sets January 29 Date to Unveil Q2 FY2026 Results - TipRanks
ResMed CEO Michael Farrell Plans Further Insider Share Sale Under Rule 144 - TipRanks
Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 - The Manila Times
Dow Theory LettersResmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026 - FinancialContent
Resmed Insider Sold Shares Worth $1,240,065, According to a Recent SEC Filing - MarketScreener
Will ResMed Inc. stock deliver stable dividendsJuly 2025 Action & Verified Short-Term Plans - ulpravda.ru
How ResMed Inc. (RME) stock performs during market turbulenceQuarterly Trade Summary & Daily Growth Stock Investment Tips - ulpravda.ru
Is ResMed Inc. (RME) stock protected from inflationEntry Point & AI Enhanced Trading Alerts - ulpravda.ru
ResMed Officer Plans Further Share Sale Under Rule 144 - MSN
Here's Why ResMed (RMD) is a Strong Growth Stock - Yahoo Finance
An excellent week for ResMed Inc.'s (NYSE:RMD) institutional owners who own 69% as one-year returns inch higher - Yahoo Finance
Resmed Receives FDA Clearance for AI-Personalized CPAP Mask Settings - San Diego Business Journal
Is This the Right Time to Add Resmed Stock to Your Portfolio? - Yahoo Finance
ResMed Director Peter Farrell Plans Additional Insider Share Sale Under Rule 144 - TipRanks
ResMed General Counsel Discloses Small Share Sale Under 10b5-1 Trading Plan - TipRanks
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
3.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):